<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00885651</url>
  </required_header>
  <id_info>
    <org_study_id>13-5-23-9-3-8-15</org_study_id>
    <secondary_id>EudraCTnr. 2008-001908-23</secondary_id>
    <nct_id>NCT00885651</nct_id>
  </id_info>
  <brief_title>Ability of Metoprolol to Alter the Exercise Induced Elevation of Catecholamines</brief_title>
  <acronym>MEXICHO</acronym>
  <official_title>A Randomised, Double Blinded, Crossover Study of the Influence of Metoprolol on Exercise Induced Elevation of Catecholamines in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure is a frequent disease in Denmark, and it is associated with very high
      mortality. Around 60,000 people in Denmark have heart failure, and there is about 11,000
      hospitalizations every year due to this disease. From the time of diagnosis, patients survive
      an average of 4-5 years.

      A critical illness mechanism in heart failure is that these patients have high blood levels
      of catecholamines; epinephrine and norepinephrine, which is stress hormones from the
      sympathetic nervous system. Standard treatment of heart failure is with the two medical
      preparations betablockers and ACE-inhibitors.

      It is not known what effect betablocker-treatment have on blood concentration of epinephrine
      and norepinephrine.

      It is the purpose of this study, to investigate the effect of Selo-Zok ® (metoprolol) on the
      blood concentration of epinephrine and norepinephrine. This is done by creating a stress
      condition for the body, in this case with the bicycle test, while doing blood samples to
      determine the concentration of catecholamines. This will be done by 1-week treatment of
      tablet Selo-Zok ® followed by 1-week treatment of placebo (a substance with no medical
      effect). Blood samples will be taken to determine small changes in inheritance material (DNA)
      in the form of point mutations also called single nucleotide polymorphisms, since these
      changes can affect how we respond to metoprolol treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in stress-triggered response of catecholamines.</measure>
    <time_frame>2 weeks and 3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in stress-triggered blood pressure response.</measure>
    <time_frame>2 weeks and 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stress-triggered pulse response.</measure>
    <time_frame>2 weeks and 3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metoprolol for 10 days followed by placebo for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 7 days followed by Metoprolol for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolole (Selo-Zok ®)</intervention_name>
    <description>Tablets, 200 mg, once a day, 10 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Kaukaser

          -  Healthy men

          -  18 years &lt; age &lt; 30 years

          -  Non-smoker

          -  18 &lt; BMI &lt; 25

          -  No chronic diseases

          -  Motor-disability that disables completement of cardio-pulmonary exercise-test.

        Exclusion Criteria:

          -  Alcohol abuse or any other abuse

          -  Intake of any narcotic drugs (example: cannabinoids, narcotics, stimulants of central
             nervous system, hypnotics, hallucinogenes)

          -  Any of following medication:

               -  astmamedication

               -  heartmedication

               -  antihistamines

               -  antipsycotics

               -  NSAIDs

               -  rifampicine

               -  chinidine

               -  glucocorticoids

          -  Abnormal ECG, particularly 2. or 3. degree AV-block, sinusbradycardia, sick
             sinusnode-syndrome, sign of heart failure or ischemia.

          -  Allergy or intolerance of metoprolole

          -  Lactoseallergy

          -  110 mmHg &lt; Systolic blood pressure &lt; 140 mmHg

          -  60 mmHg &lt; Diastolic blood pressure &lt; 90 mmHg

          -  Bloodsucker &gt; 11,1 mmol/L, or fasting, venous bloodsucker &gt;= 7,0 (measured if: 7,8 &lt;
             BS &lt; 11,1)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik HP Enghusen Poulsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Universityhospital of Copenhagen</affiliation>
  </overall_official>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2009</study_first_submitted>
  <study_first_submitted_qc>April 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2009</study_first_posted>
  <last_update_submitted>April 21, 2009</last_update_submitted>
  <last_update_submitted_qc>April 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Morten Petersen, Department of Clinical Pharmacology, Rigshospitalet, Denmark</name_title>
    <organization>Morten Petersen, Department of Clinical Pharmacology, Rigshospitalet, Denmark</organization>
  </responsible_party>
  <keyword>SNP</keyword>
  <keyword>catecholamines</keyword>
  <keyword>metoprolole</keyword>
  <keyword>healthy subjects</keyword>
  <keyword>physiological stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 12, 2011</submitted>
    <returned>September 16, 2011</returned>
    <submitted>October 19, 2011</submitted>
    <returned>November 23, 2011</returned>
    <submitted>May 1, 2014</submitted>
    <returned>May 29, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

